Cue Biopharma closes IPO with $66.2M in gross proceeds
Cue Biopharma announced the closing of its initial public offering of 8,820,710 shares of its common stock at a public offering price of $7.50 per share on December 27. The gross proceeds from the offering were approximately $66.2M, before deducting underwriting discounts and commissions and other offering expenses. Shares of the stock will begin trading today on The NASDAQ Capital Market under the ticker symbol "CUE." MDB Capital Group acted as sole book-running manager for the offering. Feltl and Company, Inc. acted as qualified independent underwriter for the offering. A registration statement relating to the securities offered and sold in the offering was filed with, and declared effective by, the Securities and Exchange Commission on December 14.